AtriCure
Update in progressATRC (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Instruments & Supplies
AtriCure, Inc. develops, manufactures, and sells medical devices for surgical cardiac ablation, left atrial appendage exclusion, and temporary nerve blockade to treat pain. The portfolio includes RF ablation systems, cryoablation products, EPi-Sense systems for atrial fibrillation, cryoSPHERE and cryoXT probes, AtriClip with disposable applicator, LARIAT, Lumitip dissectors, Glidepath guides, and Subtle Cannulas, plus reusable instruments. Headquartered in Mason, Ohio.
Company score
- Sentiment
- 0.31
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.06
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.30
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMr. Michael H. Carrel
- Founded2000
- Employees1,350
- Websitewww.atricure.com
Identifiers
- ISINUS04963C2098
- FIGIBBG000BL6CB5
- CUSIP04963C209
- CIK0001323885